A pharma product launch is the work of preparing a new medicine, and the market around it, so the right patients can get it from day one. That means evidence, access, medical readiness, peer education and operations, all timed to an approval date you don’t fully control.
Launches are hard. McKinsey found that about two-thirds of new drugs missed prelaunch consensus sales expectations in their first year, in a study of 210 launches from 2003 to 2009 (McKinsey). First-time launchers have it harder still. In McKinsey’s 2021 analysis, only 39 percent of first-time launches beat analysts’ forecasts, compared with almost half for experienced launchers (McKinsey).
The FDA’s Center for Drug Evaluation and Research (CDER) approved 46 novel drugs in 2025 (FDA), and each one needs a launch plan. This guide is written for smaller companies, especially those launching for the first time.
Why pharma product launches miss
Most misses come down to a few things that are visible early:
- Planning starts too late. Access, evidence and medical work need a long runway.
- HCPs don’t know the data at launch. Peer education isn’t ready when the label is.
- Access lags. Payers haven’t seen the value story in time.
- Operations break under pressure. Contracts, venues, payments and reporting pile up just as volume spikes.
- The first months set the trajectory. McKinsey found that drugs that start below expectations typically keep underdelivering for the next two years.
Pharma launch strategy: five building blocks
A pharma launch strategy answers five questions. The answers depend on the product, but the questions don’t.
- Who benefits most, and how will they be found? Define the patient segments and the HCPs who treat them.
- What evidence will convince prescribers and payers? Plan publications, congress data and real-world evidence.
- Which experts will help explain the science? Map and engage KOLs early through medical affairs. See our KOL engagement guide and our KOL launch strategy.
- How will HCPs learn about it after approval? Decide the mix of field teams, peer-to-peer speaker programs, digital and medical education. Our guide to HCP engagement strategies covers the options.
- Can operations keep up? Speaker contracts, events, payments and transparency reporting need to work from week one.
Pharmaceutical launch plan: a typical timeline
| When | Focus |
|---|---|
| 18–24 months before expected approval | Market research, patient segments, evidence plan, early KOL mapping |
| 12 months before | Advisory boards on data and positioning, access strategy, launch budget |
| 6 months before | Speaker bureau design: speaker identification, contracting and training plan; event and vendor partners chosen |
| 3 months before | Approved-label scenarios, program waves planned, systems and reporting tested |
| Approval and launch | Final materials reflect the approved label; speaker training; first programs |
| First 6 months | Track uptake against forecast, gather HCP feedback, adjust quickly |
These are typical lead times. First-time launchers often benefit from starting earlier.
For pre-launch advisory boards, see our guide to pharma advisory boards.
Compliance before and after approval
Before FDA approval, promotion is tightly restricted. Under 21 CFR 312.7, a sponsor or investigator must not “represent in a promotional context that an investigational new drug is safe or effective” for the uses under investigation, or commercially distribute it before approval. The regulation isn’t meant to restrict the full exchange of scientific information, but context and content matter. Pre-approval activities, including publications and congress presentations, should be reviewed so they stay scientific and non-promotional. Medical affairs, regulatory and legal teams should guide engagement during this period.
Plan promotional speaker programs around the expected approval date, but run them only after approval. Materials must be consistent with the approved labeling, and speaker training should cover the permitted claims. After launch, the usual speaker program expectations apply: a legitimate educational purpose, appropriate venues and meals, fair market value speaker arrangements, and accurate records of reportable transfers of value. Repeat attendance should be assessed against the OIG’s guidance, the voluntary PhRMA Code (which allows it where there’s a bona fide educational need) and your own policy, rather than treated as automatic. See our guides to the OIG Special Fraud Alert and Sunshine Act reporting.
Getting peer education ready for day one
For many specialty launches, peer-to-peer education is one of the fastest ways to help HCPs understand a new medicine. The work starts months before approval:
- Identify and contract speakers in advance, at fair market value, so they’re ready once the label is final. See our tips for a stronger speakers bureau.
- Train speakers on the approved deck as soon as it’s final. See our speaker briefing guide.
- Plan program waves by region and specialty, with venues and caterers lined up. See our guide to pharmaceutical event planning.
- Set budgets using our speaker program budget benchmarks.
Launch excellence checklist
- Launch planning started 18+ months before expected approval
- Patient segments and target HCPs defined
- Evidence and publication plan in place
- KOLs mapped and engaged through medical affairs
- Access and payer strategy ready before approval
- Speakers identified, contracted and scheduled for training
- Event, venue and payment processes tested
- Open Payments tracking in place from the first program
- Launch metrics and a forecast agreed
How to measure the first six months
Track leading indicators, not just sales:
- Uptake against forecast, at the brand level.
- Reach of education: how many target HCPs attended programs or engaged with medical content.
- Access: formulary wins and time to coverage.
- HCP feedback: questions and objections from programs and the field.
- Operational health: program cancellations, time to pay speakers, reporting accuracy.
Don’t choose or judge individual speakers or attendees by their prescribing. The OIG’s Special Fraud Alert lists that among its warning signs.
Common mistakes first-time launchers make
- Treating launch as a marketing project. It needs medical, access, compliance and operations from the start.
- Building the speaker bureau after approval. Contracting and training take months.
- Underestimating operations. Small teams get swamped by contracts, venues and payments in the launch quarter.
- Changing plans too slowly. The first months set the trajectory, so review data monthly.
How ZHM helps with launch
ZHM helps small and mid-sized companies get peer education ready for launch. Our speaker bureau management team handles speaker identification, contracting and training logistics. Our pharmaceutical event management team plans program waves, venues and payments.
Zvent.ai, our HCP engagement platform, keeps approvals, spend and Open Payments data in one place from the first program. See how we worked with Verrica Pharmaceuticals, or try Zvent.ai free.
This article is general information, not legal or regulatory advice. Talk to your regulatory, legal and compliance teams about your launch.
FAQ
What is a pharma launch strategy?
A pharma launch strategy is the plan for bringing a new medicine to market. It covers patient segments, evidence, KOL and medical work, HCP education, market access and operations, timed to approval.
When should pharma launch planning start?
Many teams start 18 to 24 months before the expected approval date. First-time launchers often benefit from starting earlier.
Can you run speaker programs before FDA approval?
Not promotional speaker programs. Before FDA approval, companies must not promote an investigational drug as safe or effective for the uses under investigation. Scientific exchange may be permissible, but the content, context and purpose of pre-approval activities matter. Promotional speaker programs should begin only after approval, using materials consistent with the approved labeling. Consult your legal, regulatory and compliance teams.
What is launch excellence in pharma?
Launch excellence means a launch that is planned early, coordinated across functions, and adjusted quickly using early data.
How can a small company launch without a large field force?
Many combine a smaller field team with peer-to-peer speaker programs, digital channels and an outsourced partner for events and logistics. See our outsourced vs in-house analysis.
